syn-tech chem.& pharm.co.,ltd industry forum”Ÿ泰法說會2020-英文.pdfgross profit 288 220...
TRANSCRIPT
Industry Forum
SYN-TECH CHEM.& PHARM.CO.,LTD
Andrew Wang General Manager
12 Nov. 2020
Stock Code:1777
In these presentations and discussions, there are certain forward looking
statements regarding the results of operation, financial condition and
current expectation about future events. As forward-looking statements
relate to events and depend on circumstances in the future, they involve
risk and uncertainty.
We do not undertake any obligation to publicly revise or update any
forward looking statements for availability of new information, future
events or otherwise. Real result probably differ substantially from those
expected in these forward-looking statements.
2
Brief overall
Main Products
DMF Registration Status
Official Audit Records
3
Performance for operation
Future strategies and forward-looking
Company Brief Introduction
⚫1982, Nov. 9 established
NT $300,595,500 J. M. Hsiao, Chairman 180 employees APIs
National Award in
Medicine Quality
National Award of Out
Research and Developm
Award in Pharmaceutical Te
National Innovation Award
Industrial Sustainable Excellence Aw
Small and medium enterprise Innovation Award
⚫Awards Record ⚫All-round development
Manpower cultivation Business fields Infrastructure Cooperate with
academic units Develop new drugs
with other enterprises
ISO9001 ISO14001 ISO45001 CSR
⚫ISO
5
Muscle Relaxants
Digestive System Drugs
Topical Anesthetic Agents
Respiratory System Drugs
Non- Steroidal Anti- Inflammatory
Antipyretics and Analgesic
Cardiovascular Agents
Intermediates
6
Others
COUNTRY DMF/MF(APIS)
U.S.A 16
Japan 20
Canada 2
Korea 5
Others 25
40 products have passed the TFDA PIC/S GMP inspection.
7
Name of theRegulatory Authority
1st Audit year Number /Audit
U.S.A FDA 1995 6
Taiwan FDA 2002 16
Korea FDA 2007 2
Hungary FDA 2008 1
Japan PMDA 2014 3
Mexico FDA 2015 1
EDQM 2016 1
8
Business and Financial Statements
Unit: NT in million
684
767
695
785
946
761
0
100
200
300
400
500
600
700
800
900
1000
2015 2016 2017 2018 2019 Jan.-Sept., 2020
10
11
Muscle
Relaxants
Topical
Anesthetic
Agents
Respiratory
System Drugs
Digestive
System Drugs
Cardiovascula
r Agents
Non-
Steroidal
Anti-
Inflammatory
Antipyretics
and Analgesic
Intermediates Others
Jan.-Sept., 2020 32% 13% 7% 18% 2% 2% 0% 26%
Jan.-Sept., 2019 37% 13% 6% 13% 4% 2% 2% 23%
24,287
9,979
5,765
13,473
1,6931,285
98
19,500
24,937
8,648
4,398
9,064
2,703
1,238 1,679
15,294
0%
5%
10%
15%
20%
25%
30%
35%
40%Unit: NT in ten thousand
Data collected form Jan.-Sept., 2020
12
13
Unit: NT in million
Item Jan.-Sept., 2020 Jan.-Sept., 2019 Differences
Operating revenue 761 680 81
Gross profit 288 220 68
Gross profit ratio 38% 32% 6%
Operating profit 205 142 63
Profit before tax 189 163 26
Profit after tax 152 128 24
EPS (in dollar) 5.05 4.27 0.78
14
Unit: NT in dollar
5.20 5.27
1.99
5.12 5.31
5.05
3.5 3.5
1.75
3.3 3.5
0.00
1.00
2.00
3.00
4.00
5.00
6.00
2015 2016 2017 2018 2019 Jan.-Sept., 2020
EPS Cash divident
▪ a. Revenue• The sell in API for attention deficit/hyperactivity disorder
continuously increased after it was brought to the market.
• The APIs for digestive system, topical anesthetic andantibacterial are stable growing this year.
• The sell of APIs with small quantity but high unit priceincreased this year.
▪ b. Profit• We extended our focus on the market of Europe, America
and Japan, and their business was not affected afterreasonably adjusted the price for several products.
• The sell of several products with better gross profit marginincreased.
• By improving manufacturing process, several of our productsobtained better profit.
15
Strategy in the Future Development & forward-looking
⚫ Continue to develop new product and expand theirmarket share.
⚫ Continue to improve the manufacture process forexisting products to enhance the competitiveness andprofitability :
• Shorten the manufacture process and improve the overallyield.
• Continue to improve the synthetic approach; so that enableto prevent the unexpected incidences during the manufacture.
17
⚫ Carefully select and evaluate suitable new niche APIsfor company’s future development:• Utilize the advantages of technology and equipment in our
company.
• Choice the products with high-tech threshold and high added-on value.
⚫ Expanding New Business Area:• APIs’ key intermediates.
• Continue to development our business in China market.
• Formulated APIs.
• Macromolecular APIs.
• Cooperate with other companies to develop new medicines.
18
SYN-TECH CHEM.& PHARM.CO.,LTD
生泰合成工業股份有限公司
Thanks for your attention.